Company
Bioline RX Ltd
NASDAQ:BLRX
BioLineRx is a clinical-stage, publicly-traded, (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company's declared aim is to develop products suitable for today's pharmaceutical market satisfying an unmet medical need or exhibiting features and benefits above those of current therapies.
6 stories
Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040
Meanwhile, Maxim was also pleased with the study of BL-8040 as a stem cell mobilizer for bone marrow transplants moving ahead of schedule
BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim
The BL-8084 platform continues to make progress across multiple indications and data from several studies is expected in 2018
BioLineRx reports rosy results from Phase2a trial for its cancer drug BL-8040
When BL-8040 is taken in combination with the chemotherapy drug Cytarabine, the life of patients with relapsed acute myeloid leukemia is extended by several months
Trending: American Apparel, Twitter, McDonald’s, Naked Brands, Oncomed Pharma & more
Clothing retailer American Apparel was given the green light to exit bankruptcy, and now a group of hedge funds are set to takeover the group.
BioLineRx’s celiac treatment gets designation as Class IIb medical device in Europe
The Israeli company expects to commence the next clinical efficacy study in mid-2016.